[{"orgOrder":0,"company":"Fundaci\u00f3n Santiago Dexeus Font","sponsor":"Regen Lab","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Procaine","moa":"Sodium channel alpha subunit","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Fundaci\u00f3n Santiago Dexeus Font","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Injection","sponsorNew":"Fundaci\u00f3n Santiago Dexeus Font \/ Regen Lab","highestDevelopmentStatusID":"11","companyTruncated":"Fundaci\u00f3n Santiago Dexeus Font \/ Regen Lab"}]

Find Clinical Drug Pipeline Developments & Deals for RAVOCAINE; NOVOCAIN W/ LEVOPHED-1

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fundación Santiago Dexeus Font

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Fundación Santiago Dexeus Font

                          Country arrow
                          CPhI Korea
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 23, 2024

                          Lead Product(s) : Procaine

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase IV

                          Sponsor : Regen Lab

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank